Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. (PubMed, Cell Rep Med) - Sep 3, 2026 - "Accordingly, enfortumab vedotin plus PD-1 inhibitor shows enhanced antitumor activity in vivo. These preclinical findings provide mechanistic hypotheses that may be relevant to the improved clinical outcomes observed for enfortumab vedotin plus pembrolizumab relative to chemotherapy."
Journal • Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
|
|
Albina Nesterova; Anthony Cao; Bernard A Liu; Christine O'Day; Christopher Carosino; Devra J Olson; Disha Sahetya; Elena Tenn; Gabriele Blahnik-Fagan; Gregory L Szeto; John Gosink; Katie Snead; Kelly Hensley; Margo Zaval; Masashi Shimazaki; Patrick Younan; R Greg Stacey; Ryan A Heiser; Sharsti Sandall; Shyra J Gardai; Taisuke Nakazawa; Timothy S Lewis
|